Showing 721 - 740 results of 19,650 for search '(( significantly increased decrease ) OR ( significant ((non decrease) OR (a decrease)) ))', query time: 0.72s Refine Results
  1. 721
  2. 722
  3. 723
  4. 724

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. by Rostam M. Razban (22232522)

    Published 2025
    “…The corresponding Kolmogorov-Smirnov pairwise tests are not significant (S5 Table in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0331085#pone.0331085.s001" target="_blank">SI</a>). …”
  5. 725

    5-HT inhibits <i>P</i>. <i>berghei</i> infection in mosquitoes. by Li Gao (131516)

    Published 2024
    “…(B and D) The abundance of each metabolite was normalized to the mean value of the healthy groups and shown as log2. Significantly altered metabolites (B-H FDR < 0.1, log<sub>2</sub>(FC) > 1) are highlighted in blue (decreased) and red (increased), respectively. …”
  6. 726
  7. 727
  8. 728
  9. 729
  10. 730
  11. 731
  12. 732
  13. 733
  14. 734

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  15. 735

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  16. 736

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  17. 737
  18. 738
  19. 739
  20. 740